Mallinckrodt is just one of many big-name pharma companies that are divesting non-core businesses in order to target specific therapeutics and disease areas.
Johnson & Johnson swallowed hard and upped its bid for Swiss biotech Actelion, winning the deal with a $30.2 billion bid.
Francisco Partners sold its portfolio company, CoverMyMeds, to McKesson Corp., which has partnered with CoverMyMeds since 2010.
Deal volume has trended downward in 2016, after spiking in the second quarter with a total of 421 deals.
Some large and small healthcare players are shifting their portfolios to focus on the hemostasis analyzer market, which is expected to reach nearly $5 billion by 2021.
The Behavioral Health sector isn’t charging into the New Year. Only two deals have been announced in the first three weeks of January, but one of those is unusual for the sector. On January 11, 2017, Global Partner Acquisition Corp. (NASDAQ: GPAC), a blank-check company formed for the purpose of effecting a business combination, merged […]
Last week, the Urgent Care Association of America (UCAOA) released its annual Benchmarking Report. In it was the finding that the number of urgent care centers increased 10% in 2016, to 7,357 centers. Looking through our database, it’s obvious that the majority of that year-over-year growth in urgent care centers was de novo, not from […]
The Pharmaceutical sector hasn’t wasted any time getting busy in the New Year. As of January 18, 2017, 10 pharma deals have been announced, with disclosed prices totaling $7.18 billion. Of course, the annual JP Morgan Healthcare Summit, held this year from January 9 to January 13, helped to boost the announcements. The largest deal so […]